4/25
08:10 am
cmpx
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated [Yahoo! Finan
Medium
Report
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated [Yahoo! Finan
4/25
08:00 am
cmpx
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Medium
Report
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
4/16
01:18 pm
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Low
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
4/16
08:20 am
cmpx
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors [Yahoo! Finance]
Low
Report
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors [Yahoo! Finance]
4/16
08:00 am
cmpx
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
Low
Report
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors
4/12
08:03 am
cmpx
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference [Yahoo! Finance]
Low
Report
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference [Yahoo! Finance]
4/12
08:00 am
cmpx
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
Low
Report
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
4/10
08:00 am
cmpx
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
Medium
Report
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
4/9
12:12 pm
cmpx
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
Low
Report
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]
4/9
12:00 pm
cmpx
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Low
Report
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
3/22
10:24 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Low
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
3/21
11:13 am
cmpx
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Compass Therapeutics, Inc. (NASDAQ: CMPX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
3/21
09:18 am
cmpx
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/21
09:00 am
cmpx
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
Medium
Report
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update
3/12
06:42 am
cmpx
With 52% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional owners [Yahoo! Finance]
Medium
Report
With 52% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional owners [Yahoo! Finance]
2/29
08:00 am
cmpx
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Low
Report
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
2/28
08:14 am
cmpx
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial [Yahoo! Finance]
Low
Report
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial [Yahoo! Finance]
2/28
08:00 am
cmpx
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
Low
Report
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
2/8
02:05 pm
cmpx
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know [Yahoo! Finance]
1/31
07:38 am
cmpx
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate [Yahoo! Finance]
High
Report
We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate [Yahoo! Finance]